<html lang="en"><head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width">
<title>Development Pipeline | Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.</title>
<meta name="keywords" content="">
<meta name="description" content="">
<meta property="og:title" content="Development Pipeline | Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.">
<meta property="og:type" content="article">
<meta property="og:description" content="">
<meta property="og:url" content="http://www.chugai-pharm.co.jp/english/ir/product/pipeline.html">
<meta property="og:image" content="https://www.chugai-pharm.co.jp/english/common/images/ogp.png">
<meta property="og:site_name" content="CHUGAI PHARMACEUTICAL CO., LTD.">
 
<!-- Google Tag Manager -->
<script type="text/javascript" async="" src="https://www.google-analytics.com/plugins/ua/linkid.js"></script><script async="" src="//uh.nakanohito.jp/uhj2/uh.js"></script><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=G-MGKB8NCRB2&amp;l=dataLayer&amp;cx=c"></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=G-61MXN3NRMJ&amp;l=dataLayer&amp;cx=c"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MNJXND"></script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-MNJXND');</script>
<!-- End Google Tag Manager -->


<link rel="stylesheet" href="/common/css/style.css">
<link rel="stylesheet" href="/common/lightbox/featherlight.min.css">
<link rel="stylesheet" href="/common/lightbox/lightBoxCustom.css">
<link href="//c.marsflag.com/mf/mfx/1.0/css/mfx-sbox.css" rel="stylesheet" type="text/css" media="all" charset="UTF-8">
<script src="/common/js/jquery.min.js"></script>
<script src="/common/js/script.js"></script>
<script src="/common/js/jquery.easing.1.3.js"></script>
<script src="/common/lightbox/featherlight.min.js"></script>
<script src="/common/lightbox/lightBoxCustom.js"></script>


</head>
<body id="crp" class="english ir product pipeline">

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MNJXND"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
	<div id="overlay"></div>

<div class="mf_finder_header"><div class="searchArea"><div class="innerLarge"><div class="my-search-box-sp_closeBtn"><a href="javascript:void(0);"><img src="/common/lightbox/images/featherlight-close-icon_sp.png" alt="close"></a></div> <div class="mf_finder_searchBox my-search-box-sp mf_finder_searchBox_useSelects"><form method="get" action="/english/search.html" class="mf_finder_searchBox_form"><input type="hidden" name="page" value="1"> <input type="hidden" name="d" value=""> <div class="mf_finder_searchBox_items_wrapper"><div class="mf_finder_searchBox_items"><label class="mf_finder_searchBox_doctype" style="display: none;"><select name="doctype" class="mf_finder_searchBox_doctype_select"><option value="all">All</option> <option value="html">html</option><option value="pdf">pdf</option><option value="doc">doc</option><option value="xls">xls</option><option value="ppt">ppt</option></select></label> <div class="mf_finder_searchBox_query_wrap"><input type="text" name="q" autocomplete="off" title="search query" placeholder="search" class="mf_finder_searchBox_query_input"> <!----></div> <button type="submit" class="mf_finder_searchBox_submit"><span></span></button></div></div> <div class="mf_finder_searchBox_selects" style="display: none;"><!----> <!----> <div class="mf_finder_searchBox_misc"><!----> <label class="mf_finder_searchBox_sort"><select name="sort" class="mf_finder_searchBox_sort_select"><option class="mf_finder_searchBox_sort_opt_0" value="0">match</option><option class="mf_finder_searchBox_sort_opt_1" value="1">recent</option></select></label> <label class="mf_finder_searchBox_pagemax"><select name="pagemax" class="mf_finder_searchBox_pagemax_select"><option class="mf_finder_searchBox_pagemax_opt_1" value="10">10</option><option class="mf_finder_searchBox_pagemax_opt_2" value="20">20</option><option class="mf_finder_searchBox_pagemax_opt_3" value="30">30</option></select></label> <label class="mf_finder_searchBox_imgsize"><select name="imgsize" class="mf_finder_searchBox_imgsize_select"><option class="mf_finder_searchBox_imgsize_opt_0" value="0">none</option><option class="mf_finder_searchBox_imgsize_opt_1" value="1">small</option><option class="mf_finder_searchBox_imgsize_opt_2" value="2">medium</option><option class="mf_finder_searchBox_imgsize_opt_3" value="3">large</option></select></label></div></div></form></div></div></div> <header id="header"><div class="innerLarge"><div class="headerTop"><h1 class="logo"><a href="/english/index.html"><img src="/english/common/images/pc/logo.svg" alt="CHUGAI PHARMACEUTICAL CO., LTD." class="switch"></a></h1> <div class="rightBox"><nav id="sNavi"><ul><li><a href="/index.html">Japanese</a></li> <li><a href="/english/rule/contact/index.html">Contact</a></li> <li><a href="/english/rule/sitemap/index.html">Sitemap</a></li></ul></nav> <div id="searchBox" class="sp"><a href="javascript:void(0);"><img src="/common/images/pc/head-search-icon.png" alt="SEARCH" class="switch"></a></div></div> <div id="spMenu"><a href="javascript:void(0);" class="menuBtn"><img src="/common/images/sp/menu-icon.png" alt="Menu"></a></div></div> <div id="menuSP" class="pushy pushyRight" style=""><div class="pushyContent"><div id="menuCloseSP"><p><a href="javascript:void(0);" class="pushyLink"></a></p></div> <ul class="topMenu"><li><a href="/english/profile/group/office.html">Offices &amp; Branches</a></li> <li><a href="/english/news/index.html">News</a></li> <li><a href="/index.html">Japanese</a></li></ul> <ul id="menuInnerSP"><li class="hasAccButton"><a href="/english/profile/index.html" class="pr138 ">About Chugai</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <div class="menusArea"><ul><li><a href="/english/profile/message/index.html">Message from the CEO</a></li> <li><a href="/english/profile/strengths/index.html">Chugai’s Five Strengths</a></li> <li class="hasAccButton"><a href="/english/profile/about/index.html">Company Outline</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/about/outline.html">Company Profile</a></li><li><a href="/english/profile/about/value.html">Value Creation Model</a></li><li><a href="/english/profile/about/process.html">Business Processes</a></li><li><a href="/english/profile/about/directors_officers.html">Directors &amp; Officers</a></li><li><a href="/english/profile/about/organization.html">Organization</a></li><li><a href="/english/profile/about/reports.html">Company Brochure &amp; Reports</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/vision/index.html">Our Vision</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/vision/philosophy.html">Mission Statement and Chugai Group Code of Conduct</a></li><li><a href="/english/profile/vision/slogan.html">Slogan</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/strategy/index.html">Our Strategy</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/strategy/growth_strategy.html">Growth Strategy</a></li><li><a href="/english/profile/strategy/roche_alliance.html">Strategic Alliance with Roche</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/history/index.html">History of Chugai Pharmaceutical</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/history/index.html#tab">Turning Points</a></li><li><a href="/english/profile/history/age01.html">History of Chugai Pharmaceutical / Nippon Roche (chronology)</a></li><li><a href="/english/profile/history/origin.html">Origin of the company name and logo</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/group/index.html">Chugai Group</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/group/office.html">Offices &amp; Branches</a></li><li><a href="/english/profile/group/domestic.html">Domestic Group Companies</a></li><li><a href="/english/profile/group/overseas.html">Overseas Group Companies</a></li><li><a href="/english/profile/group/roche.html">Roche Group Websites</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/rd/index.html">R&amp;D</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/rd/process.html">R&amp;D Process</a></li><li><a href="/english/profile/rd/features.html">Research Structure and Network</a></li><li><a href="/english/profile/rd/structure.html">R&amp;D Bases</a></li><li><a href="/english/profile/rd/approach.html">Features of Drug Discovery Approaches</a></li><li><a href="/english/profile/rd/technologies.html">Platforms &amp; Technologies</a></li><li><a href="/english/profile/rd/development.html">Clinical Development</a></li><li><a href="/english/profile/rd/production.html">Production Technology</a></li><li><a href="/english/profile/rd/intellectual/index.html">Intellectual Property</a></li><li><a href="/english/profile/rd/guideline/index.html">Other Guidelines</a></li><li><a href="/english/profile/rd/glossary.html">Chugai R&amp;D Glossary</a></li></ul></li> <li class="hasAccButton"><a href="/english/profile/digital/index.html">Digital Transformation "CHUGAI DIGITAL"</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/profile/digital/vision.html">VISION</a></li><li><a href="/english/profile/digital/platform_value_chains.html">Strengthen the digital platform/Optimize all value chains</a></li><li><a href="/english/profile/digital/ai_technology.html">AI-leveraging drug discovery</a></li><li><a href="/english/profile/digital/digital_biomarkers.html">Digital biomarkers (dBM) initiatives</a></li><li><a href="/english/profile/digital/real_world_data.html">Utilization of real-world data (RWD)</a></li></ul></li> <li><a href="/english/profile/ad/index.html">Videos &amp; Advertisements</a></li> <li><a href="/english/news/index.html">News</a></li> <li><a href="/english/profile/media/conference.html">Media Conference</a></li></ul></div></li> <li class="hasAccButton"><a href="/english/ir/index.html" class="pr138 ">Investor Relations</a> <a href="javascript:void(0);" class="accButton opened"><span>close</span></a> <div class="menusArea"><ul><li class="hasAccButton"><a href="/english/ir/policy/index.html">Management Policy</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/policy/ceo.html">Message from the CEO</a></li><li><a href="/english/ir/policy/philosophy.html">Mission Statement and Chugai Group Code of Conduct</a></li><li><a href="/english/ir/policy/growth_strategy.html">Growth Strategy</a></li><li><a href="/english/ir/policy/directors_officers.html">Directors &amp; Officers</a></li><li><a href="/english/ir/policy/risk.html">Business Risks</a></li><li><a href="/english/ir/policy/disclosure.html">Disclosure Policy</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/finance/index.html">Financial Results</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/finance/latest.html">Latest Results</a></li><li><a href="/english/ir/finance/finance_other.html">Financial Results and Other Indicators</a></li><li><a href="/english/ir/finance/revenue_product.html">Revenue by Product</a></li><li><a href="/english/ir/finance/balance_sheet.html">Movements of assets and liabilities</a></li><li><a href="/english/ir/finance/cashflow.html">Movements of Free Cash Flows</a></li><li><a href="/english/ir/finance/indicators.html">Performance Indicators</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/reports_downloads/index.html">Reports &amp; Downloads</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/reports_downloads/tanshin.html">Quarterly Reports / Finance Reports</a></li><li><a href="/english/ir/reports_downloads/presentations.html">Presentation Materials</a></li><li><a href="/english/ir/reports_downloads/all_download.html">Downloads</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/share/index.html">Shareholder Information</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/share/notices.html">Notices</a></li><li><a href="/english/ir/share/agm.html">Shareholder Meetings</a></li><li><a href="/english/ir/share/info.html">Information on Shares</a></li><li><a href="/english/ir/share/shareholder_return.html">Shareholder Returns</a></li><li><a href="/english/ir/share/ownership.html">Share Ownership</a></li><li><a href="/english/ir/share/analyst_coverage.html">Analyst Coverage</a></li><li><a href="/english/ir/share/bonds_ratings.html">Bonds &amp; Ratings</a></li><li><a href="/english/ir/share/price.html">Share Price</a></li><li><a href="/english/ir/share/articles_incorporation.html">Articles of Incorporation</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/governance/index.html">Corporate Governance</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/governance/concept.html">Basic Approach</a></li><li><a href="/english/ir/governance/perspective.html">Introduction of Outside Perspectives</a></li><li><a href="/english/ir/governance/system.html">Auditing System and Internal Control System</a></li><li><a href="/english/ir/governance/remuneration.html">Officer Remuneration</a></li><li><a href="/english/ir/governance/held_shares.html">Policy regarding the strategic shareholdings</a></li><li><a href="/english/ir/governance/dialogue.html">Communication with Stakeholders</a></li><li><a href="/english/ir/governance/report.html">Corporate Governance report and related materials</a></li><li><a href="/english/ir/reports_downloads/annual_reports/files/eAR2020_12_M10.pdf">Message from an Outside Director</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/rd/index.html">R&amp;D</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/rd/policy.html">R&amp;D Strategy</a></li><li><a href="/english/ir/rd/features.html">Features of Research Platform</a></li><li><a href="/english/ir/rd/structure.html">Research Structure</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/profile/index.html">Company Outline</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/profile/business.html">Company Profile</a></li><li><a href="/english/ir/profile/organization.html">Organization</a></li></ul></li> <li class="hasAccButton"><a href="/english/ir/history/index.html">History of Chugai Pharmaceutical</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/history/index.html#tab">Turning Points</a></li><li><a href="/english/ir/history/age01.html">History of Chugai Pharmaceutical / Nippon Roche (chronology)</a></li><li><a href="/english/ir/history/origin.html">Origin of the company name and logo</a></li></ul></li> <li><a href="/english/ir/esg/index.html">ESG at Chugai</a></li> <li class="hasAccButton"><a href="/english/ir/product/index.html">Main Products / Development Pipeline</a> <a href="javascript:void(0);" class="accButton opened"><span>close</span></a> <ul><li><a href="/english/ir/product/product.html">Main Products</a></li><li><a href="/english/ir/product/pipeline.html" class="sp_here">Development Pipeline</a></li><li><a href="/english/ir/product/technologies.html">Applied Technology</a></li></ul></li> <li><a href="/english/ir/comparison/index.html">See how Chugai compares to other companies</a></li> <li><a href="/english/ir/roche_alliance/index.html">Strategic Alliance with Roche</a></li> <li><a href="/english/ir/strengths/index.html">Chugai’s Five Strengths</a></li> <li><a href="/english/ir/event/index.html">Events &amp; Presentations</a></li> <li class="hasAccButton"><a href="/english/ir/information/index.html">Contacts &amp; Information</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/ir/information/disclaimer.html">Disclaimer</a></li><li><a href="/english/ir/information/irmail.html">E-mail Alerts</a></li><li><a href="/english/ir/information/contact.html">IR Contact</a></li></ul></li> <li><a href="/english/ir/faq/index.html">FAQs</a></li></ul></div></li> <li class="hasAccButton"><a href="/english/recruit/index.html" class="pr138 ">Recruitment</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <div class="menusArea"><ul><li><a href="/english/recruit/new/index.html">Graduate Recruitment</a></li> <li><a href="/english/recruit/career/index.html">Mid-career Recruitment</a></li> <li><a href="/english/recruit/to_h/index.html">Recruitment of the Disabled</a></li></ul></div></li> <li class="hasAccButton"><a href="/english/sustainability/index.html" class="pr138 ">Sustainability</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <div class="menusArea"><ul><li class="hasAccButton"><a href="/english/sustainability/sharedvalue/index.html">Basic Policy (Creation of Shared Value)</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/sharedvalue/topcommitment.html">Top Management Commitment</a></li><li><a href="/english/sustainability/sharedvalue/philosophy.html">Mission Statement and Chugai Group Code of Conduct</a></li><li><a href="/english/sustainability/sharedvalue/policy.html">Basic Policy for Creating Shared Value</a></li><li><a href="/english/sustainability/sharedvalue/stakeholder.html">Value Shared with Stakeholders</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/strategy/index.html">Sustainability and Business Strategy</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/strategy/background.html">Context of Our Efforts to Create Shared Value</a></li><li><a href="/english/sustainability/strategy/patient.html">Our Approach to Value for Patients</a></li><li><a href="/english/sustainability/strategy/materiality.html">Chugai’s Material Issues</a></li><li><a href="/english/sustainability/strategy/sdgs.html">Chugai’s Contribution to the SDGs</a></li><li><a href="/english/sustainability/strategy/system.html">Framework for Promoting Sustainability</a></li><li><a href="/english/sustainability/strategy/riskmanagement.html">Risk Management</a></li><li><a href="/english/sustainability/strategy/it_security.html">IT Security and Information Management</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/patient/index.html">Sustainable Patient-Centric Healthcare</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/patient/effort.html">Initiatives for Sustainable Patient-Centric Healthcare</a></li><li><a href="/english/sustainability/patient/core_themes.html">Drug Safety Core Themes and Initiatives</a></li><li><a href="/english/sustainability/patient/counterfeit.html">Anti-Counterfeit Initiatives</a></li><li><a href="/english/sustainability/patient/reliability.html">Increasing Product Reliability</a></li><li><a href="/english/sustainability/patient/spotlight.html">Patient-Centric Activities to Help&nbsp;Resolve&nbsp;Social Issues in the&nbsp;Field of&nbsp;Rare Disease</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/globalhealth/index.html">Global Health</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/globalhealth/concept.html">Chugai’s Basic Approach to Global Health</a></li><li><a href="/english/sustainability/globalhealth/priority.html">Priorities in Addressing Global Health</a></li><li><a href="/english/sustainability/globalhealth/project.html">Projects We Have Joined</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/diversity/index.html">Human Resources and Diversity &amp; Inclusion</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/diversity/employee.html">Personnel Systems</a></li><li><a href="/english/sustainability/diversity/message.html">Message from Management on D&amp;I</a></li><li><a href="/english/sustainability/diversity/vision.html">D&amp;I Vision and Performance</a></li><li><a href="/english/sustainability/diversity/system.html">D&amp;I Promotion System</a></li><li><a href="/english/sustainability/diversity/promotion.html">Initiatives to Promote the Success of Diverse Employees</a></li><li><a href="/english/sustainability/diversity/worklife/index.html">Facilitating Work/Life Balance</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/ethics/index.html">Ethics and Compliance</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/ethics/effort.html">Initiatives for Ethics and Compliance</a></li><li><a href="/english/sustainability/ethics/healthcare.html">Healthcare Compliance based on the Chugai Code of Practice</a></li><li><a href="/english/sustainability/ethics/biotechnology.html">Biotechnology Policies</a></li><li><a href="/english/sustainability/ethics/human_stem_cells.html">Policy on Research Using Human Stem Cells</a></li><li><a href="/english/sustainability/ethics/animals.html">Policy for Research by Animals</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/supplychain/index.html">Supply Chain Management</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/supplychain/policy.html">Measure, Purchasing Policy and Chugai Ethical Purchasing Standards</a></li><li><a href="/english/sustainability/supplychain/evaluation.html">Creation of a System for Comprehensive Assessment of Suppliers</a></li><li><a href="/english/sustainability/supplychain/emergencymeasure/index.html">Response in Emergencies</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/humanrights/index.html">Human Rights</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/humanrights/policy.html">Chugai Group Human Rights Statement</a></li><li><a href="/english/sustainability/humanrights/effort.html">Education regarding respect for human rights</a></li><li><a href="/english/sustainability/humanrights/trials.html">Our Approach to Clinical Trials</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/community/index.html">Social Contribution</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/community/concept.html">Five Priority Areas</a></li><li><a href="/english/sustainability/community/support/index.html">Disaster support activities</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/environment/index.html">Environment</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/environment/policy.html">Environmental, Health and Safety Policy/Basic Approach</a></li><li><a href="/english/sustainability/environment/system.html">EHS Promotional Activities System</a></li><li><a href="/english/sustainability/environment/action.html">Goals and Initiatives</a></li><li><a href="/english/sustainability/environment/climate.html">Climate Change Countermeasures</a></li><li><a href="/english/sustainability/environment/tcfd.html">Disclosures based on the TCFD recommendations</a></li><li><a href="/english/sustainability/environment/resource.html">Use of renewable/recycled resources</a></li><li><a href="/english/sustainability/environment/biodiversity.html">Protection of Biodiversity</a></li><li><a href="/english/sustainability/environment/communication.html">Education and Training</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/healthmanagement/index.html">Health and Productivity Management</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/healthmanagement/policy.html">Environmental, Health and Safety Policy/Basic Approach</a></li><li><a href="/english/sustainability/healthmanagement/system.html">EHS Promotional Activities System</a></li><li><a href="/english/sustainability/healthmanagement/healthdeclaration.html">Chugai Group Declaration on Health</a></li><li><a href="/english/sustainability/healthmanagement/healthpromotion.html">Promoting Health and Productivity Management</a></li><li><a href="/english/sustainability/healthmanagement/occupationalinjuries.html">Countermeasures against Smoking</a></li><li><a href="/english/sustainability/healthmanagement/action.html">Goals and Initiatives</a></li><li><a href="/english/sustainability/healthmanagement/activities.html">Health and Safety Activities</a></li><li><a href="/english/sustainability/healthmanagement/industrialaccident.html">Preventing occupational injuries</a></li><li><a href="/english/sustainability/healthmanagement/communication.html">Education and Training</a></li></ul></li> <li><a href="/english/sustainability/governance/index.html">Corporate Governance</a></li> <li class="hasAccButton"><a href="/english/sustainability/activity/index.html">Activity Reports</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/activity/past/index.html">Past Reports</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/data/index.html">Data</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/data/policy.html">Sustainability Policy and Data</a></li><li><a href="/english/sustainability/data/diversity.html">D&amp;I Data</a></li><li><a href="/english/sustainability/data/past_report/index.html">Past Reports</a></li></ul></li> <li class="hasAccButton"><a href="/english/sustainability/transparency/index.html">Chugai's Transparency Guidelines</a> <a href="javascript:void(0);" class="accButton"><span>open</span></a> <ul><li><a href="/english/sustainability/transparency/guideline.html">Guidelines on Relation with Medical Institutions and Patient Groups</a></li><li><a href="/english/sustainability/transparency/medical.html">Payments to Medical Institutions, Healthcare Professionals, etc.</a></li><li><a href="/english/sustainability/transparency/patient.html">Disclosure of Information According to the "Guidelines for Cooperation Between Chugai and Patient Groups"</a></li></ul></li></ul></div></li> <li><a href="/english/rule/contact/index.html">Contact</a></li></ul></div></div> <div class="siteOverlay"></div> <div class="headerBottom"><nav id="gNavi"><ul><li class="profile dropMenu "><a href="/english/profile/index.html">About Chugai</a> <div class="menuArea"><div class="innerLarge"><div class="closeBtn"><a href="#"><img src="/common/lightbox/images/featherlight-close-icon.png" alt="Close"> <span>Close</span></a></div> <div class="navArea"><h2><a href="/english/profile/index.html">About Chugai</a></h2> <p>Chugai’s mission is to create innovative drugs for the benefit of patients.</p> <div class="topLinkArea"><ul><li><a href="/english/profile/index.html">Top page</a></li></ul></div> <div class="subLinkArea"><div class="txtLinkArea"><ul><li><a href="/english/profile/message/index.html">Message from the CEO</a></li> <li><a href="/english/profile/about/index.html">Company Outline</a></li> <li><a href="/english/profile/vision/index.html">Our Vision</a></li> <li><a href="/english/profile/strategy/index.html">Our Strategy</a></li> <li><a href="/english/profile/history/index.html">History of Chugai Pharmaceutical</a></li> <li><a href="/english/profile/group/index.html">Chugai Group</a></li></ul> <ul><li><a href="/english/profile/rd/index.html">R&amp;D</a></li> <li><a href="/english/profile/digital/index.html">Digital Transformation “CHUGAI DIGITAL”</a></li> <li><a href="/english/profile/ad/index.html">Videos &amp; Advertisements</a></li></ul> <ul><li><a href="/english/press/index.html">Press Room</a></li> <li><a href="/english/news/index.html">News</a></li> <li><a href="/english/profile/media/conference.html">Media Conference</a></li></ul></div> <div class="prNavArea"><ul><li><a href="/english/profile/strengths/index.html"><figure><img src="/menu_img/resources/images/1/298/menu_img.jpg" alt=""> <figcaption>Chugai’s Five Strengths</figcaption></figure></a></li></ul></div></div></div></div></div></li> <li class="ir dropMenu "><a href="/english/ir/index.html">Investor Relations</a> <div class="menuArea"><div class="innerLarge"><div class="closeBtn"><a href="#"><img src="/common/lightbox/images/featherlight-close-icon.png" alt="Close"> <span>Close</span></a></div> <div class="navArea"><h2><a href="/english/ir/index.html">Investor Relations</a></h2> <div class="topLinkArea"><ul><li><a href="/english/ir/index.html">Top page</a></li></ul></div> <div class="subLinkArea"><div class="txtLinkArea"><ul><li><a href="/english/ir/policy/index.html">Management Policy</a></li> <li><a href="/english/ir/governance/index.html">Corporate Governance</a></li> <li><a href="/english/ir/esg/index.html">ESG at Chugai</a></li></ul> <ul><li><a href="/english/ir/finance/index.html">Financial Results</a></li> <li><a href="/english/ir/share/index.html">Shareholder Information</a></li> <li><a href="/english/ir/reports_downloads/index.html">Reports &amp; Downloads</a></li> <li><a href="/english/ir/event/index.html">Events &amp; Presentations</a></li></ul> <ul><li><a href="/english/ir/information/index.html">Contacts &amp; Information</a></li> <li><a href="/english/ir/faq/index.html">FAQs</a></li></ul></div> <div class="prNavArea"><ul><li><a href="/english/ir/policy/growth_strategy.html"><figure><img src="/menu_img/resources/images/1/266/menu_img.jpg" alt=""> <figcaption>Growth Strategy</figcaption></figure></a></li> <li><a href="/english/ir/reports_downloads/annual_reports.html"><figure><img src="/menu_img/resources/images/1/321/menu_img.jpg" alt=""> <figcaption>Annual Reports</figcaption></figure></a></li></ul></div></div></div></div></div></li> <li class="recruit dropMenu"><a href="/english/recruit/index.html">Recruitment</a> <div class="menuArea"><div class="innerLarge"><div class="closeBtn"><a href="#"><img src="/common/lightbox/images/featherlight-close-icon.png" alt="Close"> <span>Close</span></a></div> <div class="navArea"><h2><a href="/english/recruit/index.html">Recruitment</a></h2> <p>It’s not just about saving lives. Helping people, changing the world.</p> <div class="topLinkArea"><ul><li><a href="/english/recruit/index.html">Top page</a></li></ul></div> <div class="subLinkArea"><div class="txtLinkArea"><ul><li><a href="/english/recruit/new/index.html">Graduate Recruitment</a></li> <li><a href="/english/recruit/career/index.html">Mid-career Recruitment</a></li> <li><a href="/english/recruit/to_h/index.html">Recruitment of the Disabled</a></li></ul></div></div></div></div></div></li> <li class="sustainability dropMenu"><a href="/english/sustainability/index.html">Sustainability</a> <div class="menuArea"><div class="innerLarge"><div class="closeBtn"><a href="#"><img src="/common/lightbox/images/featherlight-close-icon.png" alt="Close"> <span>Close</span></a></div> <div class="navArea"><h2><a href="/english/sustainability/index.html">Sustainability</a></h2> <p>We will work for the benefit of the medical community and human health while sharing value with stakeholders.</p> <div class="topLinkArea"><ul><li><a href="/english/sustainability/index.html">Top page</a></li></ul></div> <div class="subLinkArea"><div class="txtLinkArea"><ul><li><a href="/english/sustainability/sharedvalue/index.html">Basic Policy (Creation of Shared Value)</a></li> <li><a href="/english/sustainability/strategy/index.html">Sustainability and Business Strategy</a></li></ul> <ul><li><a href="/english/sustainability/patient/index.html">Sustainable Patient-Centric Healthcare</a></li> <li><a href="/english/sustainability/globalhealth/index.html">Global Health</a></li> <li><a href="/english/sustainability/diversity/index.html">Human Resources and Diversity &amp; Inclusion</a></li> <li><a href="/english/sustainability/ethics/index.html">Ethics and Compliance</a></li> <li><a href="/english/sustainability/supplychain/index.html">Supply Chain Management</a></li> <li><a href="/english/sustainability/humanrights/index.html">Human Rights</a></li> <li><a href="/english/sustainability/community/index.html">Social Contribution</a></li> <li><a href="/english/sustainability/environment/index.html">Environment</a></li> <li><a href="/english/sustainability/healthmanagement/index.html">Health and Productivity Management</a></li> <li><a href="/english/sustainability/governance/index.html">Corporate Governance</a></li></ul> <ul><li><a href="/english/sustainability/evaluation/index.html">External Evaluations</a></li> <li><a href="/english/sustainability/data/index.html">Data</a></li> <li><a href="/english/sustainability/transparency/index.html">Chugai’s Transparency Guidelines</a></li></ul></div> <div class="prNavArea"><ul><li><a href="/english/sustainability/activity/index.html"><figure><img src="/menu_img/resources/images/1/750/menu_img.jpg" alt=""> <figcaption>Activity Reports</figcaption></figure></a></li> <li><a href="/english/sustainability/community/parasports/index.html"><figure><img src="/menu_img/resources/images/1/736/menu_img.jpg" alt=""> <figcaption>Chugai Supports Para-Sports</figcaption></figure></a></li></ul></div></div></div></div></div></li> <li id="searchBox"><div class="pc search"><div class="mf_finder_searchBox my-search-box mf_finder_searchBox_useSelects"><form method="get" action="/english/search.html" class="mf_finder_searchBox_form"><input type="hidden" name="page" value="1"> <input type="hidden" name="d" value=""> <div class="mf_finder_searchBox_items_wrapper"><div class="mf_finder_searchBox_items"><label class="mf_finder_searchBox_doctype" style="display: none;"><select name="doctype" class="mf_finder_searchBox_doctype_select"><option value="all">All</option> <option value="html">html</option><option value="pdf">pdf</option><option value="doc">doc</option><option value="xls">xls</option><option value="ppt">ppt</option></select></label> <div class="mf_finder_searchBox_query_wrap"><input type="text" name="q" autocomplete="off" title="search query" placeholder="Search" class="mf_finder_searchBox_query_input"> <!----></div> <button type="submit" class="mf_finder_searchBox_submit"><span></span></button></div></div> <div class="mf_finder_searchBox_selects" style="display: none;"><!----> <!----> <div class="mf_finder_searchBox_misc"><!----> <label class="mf_finder_searchBox_sort"><select name="sort" class="mf_finder_searchBox_sort_select"><option class="mf_finder_searchBox_sort_opt_0" value="0">match</option><option class="mf_finder_searchBox_sort_opt_1" value="1">recent</option></select></label> <label class="mf_finder_searchBox_pagemax"><select name="pagemax" class="mf_finder_searchBox_pagemax_select"><option class="mf_finder_searchBox_pagemax_opt_1" value="10">10</option><option class="mf_finder_searchBox_pagemax_opt_2" value="20">20</option><option class="mf_finder_searchBox_pagemax_opt_3" value="30">30</option></select></label> <label class="mf_finder_searchBox_imgsize"><select name="imgsize" class="mf_finder_searchBox_imgsize_select"><option class="mf_finder_searchBox_imgsize_opt_0" value="0">none</option><option class="mf_finder_searchBox_imgsize_opt_1" value="1">small</option><option class="mf_finder_searchBox_imgsize_opt_2" value="2">medium</option><option class="mf_finder_searchBox_imgsize_opt_3" value="3">large</option></select></label></div></div></form></div></div></li></ul></nav></div></div></header></div>	<section id="breadcrumb" class="pc">
		<div class="innerLarge">
			<ul class="breadcrumbNavList">
																					<li><a href="/english/index.html">Home</a></li>
																																<li><a href="/english/ir/index.html">Investor Relations</a></li>
																																<li><a href="/english/ir/product/index.html">Main Products / Development Pipeline</a></li>
																										<li>Development Pipeline</li>
									
			</ul>
		</div>
	</section>
	

<article class="contents">
<div id="mainContents">

<header>
<h1 class="elTitleH1">Development Pipeline</h1>
<div class="headerBtnEnglish pc">
<a class="enBtnLink" href="/ir/product/pipeline.html"><span>View in Japanese</span></a>
</div>
</header>
<section class="sectionBlock">
    <div class="innerLarge">
        <div class="innerMiddle">
            <div class="description">
                <p>Chugai’s development pipeline is categorized to Oncology, Autoimmune Diseases, Neurology, and Other diseases.<br>View the status of our current development pipeline as of Apr 25, 2022 in a PDF format.</p>

                <ul class="listNoMarker">
                  <li><a href="/english/ir/reports_downloads/pipeline/files/220425ePipeline.pdf" target="_blank" class="icoPdf">Development Pipeline (all disease areas) [PDF 434KB]</a></li>
                  <li><a href="/english/ir/reports_downloads/pipeline/files/220425ePipelineOverview.pdf" target="_blank" class="icoPdf">Overview of Development Pipeline [PDF 985KB]</a></li>
                </ul>


            </div>
        </div>
    </div>
</section>





            <div class="linkListBox">
              <div class="innerLarge">
                <ul class="linkList">
                  <li>
                    <a href="#sec01" class="icoLink">Oncology</a>
                  </li>
                  <li>
                    <a href="#sec02" class="icoLink">Immunology</a>
                  </li>
                  <li>
                    <a href="#sec03" class="icoLink">Neuroscience</a>
                  </li>
                  <li>
                    <a href="#sec04" class="icoLink">Hematology</a>
                  </li>
                  <li>
                    <a href="#sec05" class="icoLink">Ophthalmology</a>
                  </li>
                  <li>
                    <a href="#sec06" class="icoLink">Other diseases</a>
                  </li>
                  <li>
                    <a href="#sec07" class="icoLink">Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs</a>
                  </li>
                </ul>
              </div>
            </div>


      <section class="sectionBlock">
          <div class="innerLarge">
                  <div class="description">
                      <p><span class="larger">Basic Information on Development Pipeline<sup>*</sup></span><br><span class="medium">*Exclude products that have already obtained regulatory approval</span></p>
                  </div>
          </div>
      </section>



  <section id="sec01" class="sectionBlock">
      <h2 class="elTitleH2">Oncology</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr>
                                  <td>In-house</td>
                                  <td>mid-size molecule<br>Oral</td>
                                  <td>LUNA18<br>RAS inhibitor</td>
                                  <td>Solid tumors</td>
                                  <td>LUNA18, the first project in mid-size molecule drug project, is an orally administrable cyclic peptide molecule created by Chugai’s unique APOLLO<sup>*</sup> platform. It inhibits protein-protein interaction between RAS and GEF to retain RAS in an inactive state. LUNA18 exhibits growth inhibitory activity against tumor cells with various <i>RAS</i> alterations (mutations or amplifications) and can be expected to have anti-tumor effects against cancers with <i>RAS</i> alterations where there are no therapeutic drugs yet.<br>
                                  <ul class="noticeList">
                                      <li>*APOLLO: Artificial, Peptidic, Orally available, Limitlessly Localizable Omicron</li>
                                  </ul>
                                  </td>
                              </tr>
                              <tr>
                                  <td>In-house</td>
                                  <td>antibody<br>IV</td>
                                  <td>codrituzumab/GC33<br>Anti-Glypican-3 humanized monoclonal antibody</td>
                                  <td>HCC</td>
                                  <td>GC33, a humanized monoclonal antibody created by Chugai, targets glypican-3 (GPC3), which is specifically expressed in hepatocellular carcinoma.</td>
                              </tr>
                              <tr>
                                  <td>In-house</td>
                                  <td>antibody<br>IV</td>
                                  <td>ERY974<br>Anti-Glypican-3/CD3 bispecific antibody</td>
                                  <td>Solid tumors</td>
                                  <td>ERY974 is the first T-cell redirecting antibody (TRAB) developed by Chugai. TRAB is a bispecific antibody that creates a short bridge between CD3 on T cells and tumor antigen on tumor cells to activate T cells in a tumor antigen-dependent manner, and is expected to demonstrate strong cytotoxicity against tumor cells.</td>
                              </tr>
                              <tr>
                                  <td>In-house</td>
                                  <td>antibody<br>IV</td>
                                  <td>STA551<br>Anti-CD137 agonistic Switch antibody</td>
                                  <td>Solid tumors</td>
                                  <td>STA551, a “switch antibody,” is the first application of switch antibody technology, which was developed by Chugai. Switch antibodies bind to the target antigen only where there is a high concentration of a certain “switch” molecule, which is concentrated specifically at the diseased site. STA551 binds to CD137 and activates T cells in the presence of the switch molecule ATP, but not in the absence of ATP. It therefore promises to act selectively on tumors.</td>
                              </tr>
                              <tr>
                                  <td>In-house<br>(licensed out to Roche)</td>
                                  <td>antibody<br>IV</td>
                                  <td>SOF10/RG6440<br>Anti-latent TGF-β1 monoclonal antibody</td>
                                  <td>Solid tumors</td>
                                  <td>SOF10, a monoclonal antibody created by Chugai, binds to latent TGF-β1 and inhibit the activation. By changing the immunosuppressive tumor microenvironment, such as developing fibrosis of tumor tissue, an anti-tumor effect is expected against cancers where anti-cancer drugs do not respond.</td>
                              </tr>
                              <tr>
                                  <td>In-house</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>SPYK04<br>―</td>
                                  <td>Solid tumors</td>
                                  <td>SPYK04 is a small molecule drug developed in-house by Chugai.</td>
                              </tr>
                              <tr>
                                  <td>In-house<br>(licensed out to 3<sup>rd</sup> party)</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>CKI27<br>RAF/MEK inhibitor</td>
                                  <td>Ovarian cancer<br>NSCLC</td>
                                  <td>CKI27 is an oral RAF/MEK inhibitor developed in-house by Chugai.<br>In January 2020, Chugai granted Verastem Oncology an exclusive worldwide license to manufacture, develop and commercialize CKI27.</td>
                              </tr>

                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>tiragolumab/RG6058<br>Anti-TIGIT human monoclonal antibody</td>
                                  <td>SCLC<br>NSCLC<br>NSCLC (stage III)<br>Esophageal cancer</td>
                                  <td>RG6058 is an anti-TIGIT monoclonal antibody in-licensed from Roche. TIGIT is an immune checkpoint expressed on the surface of NK cells and T cells that binds to poliovirus receptors (PVR) expressed on tumor cell surfaces. This binding is thought to allow the cancer cells to evade attack by immune cells. RG6058 restores and maintains the immune response of NK cells and T cells by blocking the binding of TIGIT to PVR, and is thus expected to demonstrate efficacy against cancer cells.</td>
                              </tr>


                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>mosunetuzumab/RG7828<br>Anti-CD20/CD3 bispecific antibody</td>
                                  <td>Follicular lymphoma</td>
                                  <td>RG7828 is a bispecific antibody in-licensed from Roche. It is expected to activate T cells and attack tumor cells by crosslinking CD3 on T cells to CD20 on B cells.</td>
                              </tr>

                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>cibisatamab/RG7802<br>Anti-CEA/CD3 bispecific antibody</td>
                                  <td>Solid tumors</td>
                                  <td>RG7802, a bispecific antibody in-licensed from Roche, is expected to activate T cells and attack tumor cells by crosslinking CD3 on T-cells to carcinoembryonic antigen (CEA) on tumor cells.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>glofitamab/RG6026<br>Anti-CD20/CD3 bispecific antibody</td>
                                  <td>Hematologic tumors</td>
                                  <td>RG6026 is a bispecific antibody in-licensed from Roche. By cross-linking CD3 on T cells with CD20 on B cells, it is expected to cause T-cell activation and proliferation and attack on the target B cells through cytokine release, resulting in antitumor effect.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>RG6194<br>Anti-HER2/CD3 bispecific antibody</td>
                                  <td>Solid tumors</td>
                                  <td>RG6194, an anti-HER2/CD3 bispecific antibody in-licensed from Roche, is expected to act against HER2-expressing cancer cells by inducing and activating T cells.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>ipatasertib/RG7440<br>AKT inhibitor</td>
                                  <td>Prostate cancer</td>
                                  <td>RG7440 is an AKT inhibitor in-licensed from Roche.</td>
                              </tr>

                              <tr>
                                  <td>Roche</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>giredestrant/RG6171<br>Selective Estrogen Receptor Degrader (SERD)</td>
                                  <td>Breast cancer<br>Breast cancer (adjuvant)</td>
                                  <td>RG6171 is a selective estrogen receptor degrader (SERD) in-licensed from Roche. It is expected to exert a stronger anti-estrogen effect by promoting the degradation of ER as well as competitively inhibiting estrogen receptor binding.</td>
                              </tr>

                              <tr>
                                  <td>Roche</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>pralsetinib/RG6396<br>RET inhibitor</td>
                                  <td>NSCLC</td>
                                  <td>RG6396 is a RET inhibitor designed to selectively target rearranged during transfection (RET) alterations, including fusions and mutations, regardless of the tissue of origin.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>cobimetinib/ RG7421<br>MEK inhibitor</td>
                                  <td>Solid tumors</td>
                                  <td>RG7421 is an MEK inhibitor in-licensed from Roche.</td>
                              </tr>


                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>




  <section id="sec02" class="sectionBlock">
      <h2 class="elTitleH2">Immunology</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr>
                                  <td>Roche</td>
                                  <td>non-antibody protein<br>IV</td>
                                  <td>efmarodocokin alfa/RG7880<br>Human IL-22 fusion protein</td>
                                  <td>Inflammatory bowel disease</td>
                                  <td>RG7880 is a human IL-22 fusion protein in-licensed from Roche. It is expected to demonstrate efficacy in treating inflammatory bowel disease by directly promoting the regenerative and protective functions of IL-22 in epithelial tissue.</td>
                              </tr>
                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>




  <section id="sec03" class="sectionBlock">
      <h2 class="elTitleH2">Neuroscience</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr>
                                  <td>In-house<br>(licensed out to Roche)</td>
                                  <td>antibody<br>SC</td>
                                  <td>GYM329/RG6237<br>Anti-latent myostatin sweeping antibody</td>
                                  <td>Neuromuscular disease</td>
                                  <td>GYM329, created by Chugai, is a next-generation antibody that applies Chugai’s proprietary antibody engineering technologies, including its recycling antibody and sweeping antibody technologies. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting myostatin, GYM329 is expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>SC</td>
                                  <td>gantenerumab/RG1450<br>Anti-amyloid-beta human monoclonal antibody</td>
                                  <td>Alzheimer’s disease</td>
                                  <td>RG1450 targets aggregate amyloid beta, with a high binding affinity to plaques in particular. It is expected to reduce cognitive deterioration by removing amyloid beta in the brain.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>prasinezumab/RG7935<br>Anti-α-synuclein monoclonal antibody</td>
                                  <td>Parkinson’s disease</td>
                                  <td>RG7935 is a monoclonal antibody that targets α-synuclein. It slows the expansion of nerve cell death by inhibiting the cell-to-cell propagation of aggregated forms of neurotoxic α-synuclein, and is expected to reduce and delay progression of the disease.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>semorinemab/RG6100<br>Anti-tau humanized monoclonal antibody</td>
                                  <td>Alzheimer’s disease</td>
                                  <td>RG6100 binds to tau proteins found in the extracellular space of the brain, and is expected to slow the deterioration of cognitive functions in Alzheimer’s disease by halting the propagation of tau via neurons.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>IV</td>
                                  <td>RG6102<br>Anti-amyloid beta/TfR1 fusion protein</td>
                                  <td>Alzheimer’s disease</td>
                                  <td>RG6102 is gantenerumab (RG1450) with a novel transferrin receptor (TfR1) binding Ab moiety to achieve efficient transport over the BBB and target Aβ engagement in the brain. It is potential for superior Aβ clearance in brain to delay progression of Alzheimer’s disease.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>nucleic acid<br>IV</td>
                                  <td>tominersen/RG6042<br>Antisense oligonucleotide targeting <i>HTT</i> mRNA</td>
                                  <td>Huntington’s disease</td>
                                  <td>RG6042 is an ASO targeting human <i>HTT mRNA</i>, which is believed to be the cause of Huntington’s disease. It has the potential to delay or slow disease progression in people with Huntington’s disease by binding specifically to <i>HTT mRNA</i>, after which synthesis of the HTT protein is inhibited.</td>
                              </tr>
                              <tr>
                                  <td>Roche<br>(development under 3<sup>rd</sup> party)</td>
                                  <td>gene therapy<br>Intramuscular injection</td>
                                  <td>RG6356/SRP-9001<br>Micro-dystrophin gene therapy</td>
                                  <td>Duchenne muscular dystrophy (DMD)</td>
                                  <td>RG6356 is an investigational gene transfer therapy developed for targeted muscle expression of micro-dystrophin, a shortened, functional dystrophin protein, that addresses the genetic cause of DMD. Sarepta manages the global study including Japan.</td>
                              </tr>
                              <tr>
                                  <td>Roche</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>ralmitaront /RG7906<br>Partial TAAR1 agonist</td>
                                  <td>Schizophrenia</td>
                                  <td>RG7906 has the novel pharmacological action of working as a partial agonist of trace amino-associated receptor Type 1 (TAAR1).</td>
                              </tr>
                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>




  <section id="sec04" class="sectionBlock">
      <h2 class="elTitleH2">Hematology</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                            
                              <tr>
                                  <td>In-house<br>(licensed out to Roche)</td>
                                  <td>antibody<br>SC</td>
                                  <td>crovalimab (SKY59)/RG6107<br>Anti-C5 recycling antibody</td>
                                  <td>Paroxysmal nocturnal hemoglobinuria (PNH)<br>Atypical hemolytic uremic syndrome<br>(aHUS)Chronic sickle cell disease</td>
                                  <td>SKY59 is a recycling antibody discovered by Chugai that inhibits the C5 complement component. The onset of a number of diseases is reported to be caused by complement activation. SKY59 is expected to inhibit cleavage of C5 to C5a and C5b, thus suppressing complement activation and improving disease conditions. In PNH, SKY59 may have a suppressive effect on hemolysis by preventing the destruction of red blood cells. Application of multiple Chugai proprietary antibody engineering technologies resulted in a prolonged half-life, and the antibody is being developed as a subcutaneous self-injection.</td>
                              </tr>
                            
                              <tr>
                                  <td>In-house</td>
                                  <td>antibody<br>SC</td>
                                  <td>NXT007<br>Anti-coagulation factor IXa/X bispecific antibody</td>
                                  <td>Hemophilia A</td>
                                  <td>NXT007, created by Chugai, is a bispecific antibody that stimulates blood coagulation using the same mode of action as Hemlibra. It is applied with Chugai’s antibody engineering technologies FAST-Ig, which enhances large-scale production of the bispecific antibody and ACT-Fc, which is expected to improve antibody pharmacokinetics. NXT007 is expected to achieve the levels of hemostasis found in healthy adults and children, and is being developed to improve convenience, including the administration device.</td>
                              </tr>

                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>





  <section id="sec05" class="sectionBlock">
      <h2 class="elTitleH2">Ophthalmology</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                            
                              <tr>
                                  <td>Roche</td>
                                  <td>antibody</td>
                                  <td>faricimab/ RG7716<br>Anti-VEGF/Ang2 bispecific antibody</td>
                                  <td>Diabetic macular edema Neovascular age related macular degeneration (nAMD)<br>Retinal vein occlusion</td>
                                  <td>RG7716, which Chugai in-licensed from Roche, is the first bispecific antibody for ophthalmology diseases. It selectively binds to vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis and vascular permeability, and angiopoietin-2 (Ang-2, an antagonist of Ang-1, which contributes to the stability of mature vessels), a destabilizer of chorioretinal vessels and inducer of vascular permeability. By simultaneously neutralizing intraocular VEGF-A and Ang-2 in wAMD and DME patients, RG7716 is expected to demonstrate better treatment outcomes and a more sustained effect than the anti-VEGF drugs that are the current standard of care.</td>
                              </tr>

                              <tr>
                                  <td>Roche</td>
                                  <td>antibody<br>injection via implant</td>
                                  <td>ranibizumab (Port Delivery System)/ RG6321</td>
                                  <td>Neovascular<br>Age-related macular degeneration (nAMD)<br>Diabetic macular edema</td>
                                  <td>“RG6321” is Port Delivery System with ranibizumab. Ranibizumab is a Fab fragment of a recombinant humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), and is already sold and supplied worldwide as Lucentis<sup>®</sup> for intravitreal administration. This product is expected to maintain visual acuity without frequent dosing by the long-term and sustained release of ranibizumab from ocular implant with the highest formulation concentration.</td>
                              </tr>

                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>





  <section id="sec06" class="sectionBlock">
      <h2 class="elTitleH2">Other diseases</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">In-house / Roche / Others</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Modality/<br>Administration</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Generic name, Development Code, Mode of Action</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 35%;" class="txtLeft">Basic Information</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr>
                                  <td>In-house</td>
                                  <td>antibody<br>SC</td>
                                  <td>AMY109<br>―</td>
                                  <td>Endometriosis</td>
                                  <td>AMY109 is the third therapeutic antibody to apply the recycling antibody engineering technology created by Chugai. Its approach differs from hormone therapy, which is the standard treatment for endometriosis, and its anti-inflammatory action is expected to provide new value to patients.</td>
                              </tr>
                              <tr>
                                  <td>In-house<br>(licensed out to 3<sup>rd</sup> party)</td>
                                  <td>antibody<br>SC</td>
                                  <td>nemolizumab/CIM331<br>Anti-IL-31 receptor A humanized monoclonal antibody</td>
                                  <td>Atopic dermatitis<br>Prurigo nodularis</td>
                                  <td>CIM331 (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody originating from Chugai. The drug is expected to improve itching and skin inflammation in atopic dermatitis by blocking IL-31, a proinflammatory cytokine, from binding to its receptor.<br>In July 2016, Chugai entered into a global license agreement granting Galderma S.A. of Switzerland exclusive rights for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. In September 2016, Chugai entered into a license agreement granting Maruho Co., Ltd., the rights for the development and marketing of nemolizumab in the skin disease area for the Japanese market. In March 2022, Maruho received regulatory approval for nemolizumab in the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective) in Japan. (Product name: Mitchga)</td>
                              </tr>
                              <tr>
                                  <td>In-house<br>(licensed out to 3<sup>rd</sup> party)</td>
                                  <td>small molecule<br>Oral</td>
                                  <td>OWL833<br>Oral non-peptidic GLP-1 receptor agonist</td>
                                  <td>Type 2 diabetes<br>Obesity</td>
                                  <td>OWL833 is an oral non-peptidic GLP-1 receptor agonist created by Chugai. GLP-1 agonists have potent hypoglycemic action and induce weight loss, but convenience for patients has been an issue because they are conventionally administered in a subcutaneous injection. Because OWL833 is orally bioavailable, it is easier for patients to take, and is thus expected to contribute to the treatment of diabetes, including through improvement of drug adherence.<br>In September 2018, Chugai licensed the worldwide development and commercialization rights for OWL833 to Eli Lilly and Company.</td>
                              </tr>
                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>


  <section id="sec07" class="sectionBlock">
      <h2 class="elTitleH2">Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of April 25, 2022)</h2>
      <div class="innerLarge">
          <div class="innerMiddle">
              <div class="cntBlock">
                  <div class="tableTypeA table overflowTable">
                      <table>
                          <thead>
                              <tr>
                                  <th scope="col" style="width: 15%;" class="txtLeft">Development<br>Request</th>
                                  <th scope="col" style="width: 13%;" class="txtLeft">Product</th>
                                  <th scope="col" style="width: 20%;" class="txtLeft">Indication</th>
                                  <th scope="col" style="width: 17%;" class="txtLeft">Development Status</th>
                              </tr>
                          </thead>
                          <tbody>

                              <tr>
                                  <td rowspan="10">First<br>development<br>request</td>
                                  <td>Xeloda</td>
                                  <td>Advanced or recurrent gastric cancer</td>
                                  <td>Approved in February 2011</td>
                              </tr>

                              <tr>
                                  <td>Tarceva</td>
                                  <td>Advanced or recurrent pancreatic cancer</td>
                                  <td>Approved in July 2011</td>
                              </tr>

                              <tr>
                                  <td>Avastin</td>
                                  <td>Advanced or recurrent breast cancer</td>
                                  <td>Approved in September 2011</td>
                              </tr>

                              <tr>
                                  <td>CellCept</td>
                                  <td>Pediatric renal transplant</td>
                                  <td>Approved in September 2011</td>
                              </tr>

                              <tr>
                                  <td rowspan="2">Herceptin</td>
                                  <td>Q3W dosage metastatic breast cancer overexpressing HER2</td>
                                  <td rowspan="2">Approved in November 2011</td>
                              </tr>

                              <tr>
                                  <td>Neoadjuvant breast cancer overexpressing HER2</td>
                              </tr>

                              <tr>
                                  <td>Kytril</td>
                                  <td>Gastrointestinal symptoms associated with radiotherapy</td>
                                  <td>Approved in December 2011</td>
                              </tr>

                              <tr>
                                  <td>Pulmozyme</td>
                                  <td>Improvement of pulmonary function in patients with cystic fibrosis</td>
                                  <td>Approved in March 2012</td>
                              </tr>

                              <tr>
                                  <td>Bactramin</td>
                                  <td>Treatment and prevention of pneumocystis pneumonia</td>
                                  <td>Approved in August 2012</td>
                              </tr>

                              <tr>
                                  <td>Avastin</td>
                                  <td>Ovarian cancer</td>
                                  <td>Approved in November 2013</td>
                              </tr>


                              <tr>
                                  <td rowspan="3">Second<br>development<br>request</td>
                                  <td>Avastin</td>
                                  <td>Recurrent glioblastoma</td>
                                  <td>Approved in June 2013 (Malignant glioma)</td>
                              </tr>
                              <tr>
                                  <td>Herceptin</td>
                                  <td>Q1W dosage postoperative adjuvant breast cancer overexpressing<br>HER2</td>
                                  <td>Approved in June 2013</td>
                              </tr>

                              <tr>
                                  <td>CellCept</td>
                                  <td>Lupus nephritis</td>
                                  <td>Approved in May 2016</td>
                              </tr>


                              <tr>
                                  <td rowspan="3">Third development request</td>
                                  <td>Tamiflu</td>
                                  <td>Additional dosage for neonates and infants younger than 12 months</td>
                                  <td>Approved in March 2017</td>
                              </tr>
                              <tr>
                                  <td>Xeloda</td>
                                  <td>Adjuvant chemotherapy in rectal cancer</td>
                                  <td>Approved in August 2016</td>
                              </tr>

                              <tr>
                                  <td>Avastin</td>
                                  <td>Additional Q2W dosage and administration for ovarian cancer</td>
                                  <td>Evaluated by the Review Committee in December 2021 as eligible for public knowledge-based application; application approved February 4, 2022, by the Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council</td>
                              </tr>



                              <tr>
                                  <td rowspan="5">Fourth development request</td>
                                  <td>Copegus</td>
                                  <td>Improvement of viraemia associated with genotype 3 chronic hepatitis C or compensated cirrhosis related to hepatitis C when administered in combination with sofosbuvir</td>
                                  <td>Approved in March 2017</td>
                              </tr>
                              <tr>
                                  <td>Xeloda</td>
                                  <td>Neuroendocrine tumor</td>
                                  <td>Submitted company opinion and waiting for evaluation by committee</td>
                              </tr>

                              <tr>
                                  <td>Avastin</td>
                                  <td>Cerebral edema induced by radiation necrosis</td>
                                  <td>Submitted company opinion and waiting for evaluation by committee</td>
                              </tr>

                              <tr>
                                  <td>Neutrogin</td>
                                  <td>Combination therapy with chemotherapy including fludarabine for relapsed/refractory acute myeloid leukemia</td>
                                  <td>Evaluated by the Review Committee in December 2021 as eligible for public knowledge-based application; application approved February 4, 2022, by the Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council</td>
                              </tr>

                              <tr>
                                  <td>CellCept</td>
                                  <td>Prevention of graft-versus-host disease in hematopoietic stem cell transplantation</td>
                                  <td>Approved in June 2021</td>
                              </tr>


                          </tbody>
                      </table>
                  </div>
              </div>

          </div>
      </div>
  </section>


</div>
</article>

<section class="sectionBlock socialBtns">
    <div class="btnBox">
      <div class="innerLarge">
        <ul class="snsList">
          <li class="btnFb btnSns"><a href="https://www.facebook.com/sharer/sharer.php?u=http://www.chugai-pharm.co.jp/english/ir/product/pipeline.html" target="_blank"><img src="/english/common/images/btn/btn_fb.png" alt="Like" class="switch"></a></li>
          <li class="btnTwitter btnSns"><a href="https://twitter.com/intent/tweet?text=Development+Pipeline&amp;url=http://www.chugai-pharm.co.jp/english/ir/product/pipeline.html&amp;via=chugai_cc" target="_blank"><img src="/english/common/images/btn/btn_twitter.png" alt="Tweet" class="switch"></a></li>
          <li class="btnLine btnSns"><a href="https://social-plugins.line.me/lineit/share?url=http://www.chugai-pharm.co.jp/english/ir/product/pipeline.html" target="_blank"><img src="/english/common/images/btn/btn_line.png" alt="LINE it!" class="switch"></a></li>
          <li class="btnMail btnSns"><a href="mailto:?subject=Development%20Pipeline | CHUGAI PHARMACEUTICAL CO., LTD.&amp;body=%0D%0A%0D%0ADevelopment%20Pipeline | CHUGAI PHARMACEUTICAL CO., LTD.%0D%0Ahttp://www.chugai-pharm.co.jp/english/ir/product/pipeline.html"><img src="/english/common/images/btn/btn_mail.png" alt="E-mail" class="switch"></a></li>
        </ul>
      </div>
    </div>
  </section>
  <div class="btnBox sp">
    <div class="innerLarge">
      <div class="enBtn">
        <a class="enBtnLink" href="/ir/product/pipeline.html">
                  <span>View in Japanese</span>
                </a>
      </div>
    </div>
  </div>


	<section id="breadcrumbBottom">
<div class="innerLarge">
			<ul class="breadcrumbNavList">
																					<li><a href="/english/index.html">Home</a></li>
																																<li><a href="/english/ir/index.html">Investor Relations</a></li>
																																<li><a href="/english/ir/product/index.html">Main Products / Development Pipeline</a></li>
																										<li>Development Pipeline</li>
									
			</ul>
</div>
</section>
<!-- 同階層のメニューが入ります -->
<section id="layerMenu">
<div class="innerLarge">
<h2 class="upperLayer"><a href="/english/ir/product/index.html">Main Products / Development Pipeline</a></h2>
<ul class="sameLayers">
<li><a href="/english/ir/product/product.html">Main Products</a></li>
<li><a class="here">Development Pipeline</a></li>
<li><a href="/english/ir/product/technologies.html">Applied Technology</a></li>

</ul>
</div>
</section>
<div class="footerMenu">
		<div class="innerLarge">
			<nav id="fNavi">
				<ul class="ctgList">
										<li class="profile"><h3 class="ctgTitle">
						<a href="/english/profile/index.html">About Chugai</a>
					</h3>
											<ul class="cntList">
														<li><a href="/english/profile/message/index.html">Message from the CEO</a></li>
														<li><a href="/english/profile/strengths/index.html">Chugai’s Five Strengths</a></li>
														<li><a href="/english/profile/about/index.html">Company Outline</a></li>
														<li><a href="/english/profile/vision/index.html">Our Vision</a></li>
														<li><a href="/english/profile/strategy/index.html">Our Strategy</a></li>
														<li><a href="/english/profile/history/index.html">History of Chugai Pharmaceutical</a></li>
														<li><a href="/english/profile/group/index.html">Chugai Group</a></li>
														<li><a href="/english/profile/rd/index.html">R&amp;D</a></li>
														<li><a href="/english/profile/digital/index.html">Digital Transformation "CHUGAI DIGITAL"</a></li>
														<li><a href="/english/profile/ad/index.html">Videos &amp; Advertisements</a></li>
														<li><a href="/english/press/index.html">Press Room</a></li>
														<li><a href="/english/news/index.html">News</a></li>
														<li><a href="/english/profile/media/conference.html">Media Conference</a></li>
							
						</ul>
										</li>
										<li class="ir"><h3 class="ctgTitle">
						<a href="/english/ir/index.html">Investor Relations</a>
					</h3>
											<ul class="cntList">
														<li><a href="/english/ir/policy/index.html">Management Policy</a></li>
														<li><a href="/english/ir/finance/index.html">Financial Results</a></li>
														<li><a href="/english/ir/reports_downloads/index.html">Reports &amp; Downloads</a></li>
														<li><a href="/english/ir/share/index.html">Shareholder Information</a></li>
														<li><a href="/english/ir/governance/index.html">Corporate Governance</a></li>
														<li><a href="/english/ir/rd/index.html">R&amp;D</a></li>
														<li><a href="/english/ir/profile/index.html">Company Outline</a></li>
														<li><a href="/english/ir/history/index.html">History of Chugai Pharmaceutical</a></li>
														<li><a href="/english/ir/esg/index.html">ESG at Chugai</a></li>
														<li><a href="/english/ir/product/index.html">Main Products / Development Pipeline</a></li>
														<li><a href="/english/ir/comparison/index.html">See how Chugai compares to other companies</a></li>
														<li><a href="/english/ir/roche_alliance/index.html">Strategic Alliance with Roche</a></li>
														<li><a href="/english/ir/strengths/index.html">Chugai’s Five Strengths</a></li>
														<li><a href="/english/ir/event/index.html">Events &amp; Presentations</a></li>
														<li><a href="/english/ir/information/index.html">Contacts &amp; Information</a></li>
														<li><a href="/english/ir/faq/index.html">FAQs</a></li>
							
						</ul>
										</li>
										<li class="recruit"><h3 class="ctgTitle">
						<a href="/english/recruit/index.html">Recruitment</a>
					</h3>
											<ul class="cntList">
														<li><a href="/english/recruit/new/index.html">Graduate Recruitment</a></li>
														<li><a href="/english/recruit/career/index.html">Mid-career Recruitment</a></li>
														<li><a href="/english/recruit/to_h/index.html">Recruitment of the Disabled</a></li>
							
						</ul>
										</li>
										<li class="sustainability"><h3 class="ctgTitle">
						<a href="/english/sustainability/index.html">Sustainability</a>
					</h3>
											<ul class="cntList">
														<li><a href="/english/sustainability/sharedvalue/index.html">Basic Policy (Creation of Shared Value)</a></li>
														<li><a href="/english/sustainability/strategy/index.html">Sustainability and Business Strategy</a></li>
														<li><a href="/english/sustainability/patient/index.html">Sustainable Patient-Centric Healthcare</a></li>
														<li><a href="/english/sustainability/globalhealth/index.html">Global Health</a></li>
														<li><a href="/english/sustainability/diversity/index.html">Human Resources and Diversity &amp; Inclusion</a></li>
														<li><a href="/english/sustainability/ethics/index.html">Ethics and Compliance</a></li>
														<li><a href="/english/sustainability/supplychain/index.html">Supply Chain Management</a></li>
														<li><a href="/english/sustainability/humanrights/index.html">Human Rights</a></li>
														<li><a href="/english/sustainability/community/index.html">Social Contribution</a></li>
														<li><a href="/english/sustainability/environment/index.html">Environment</a></li>
														<li><a href="/english/sustainability/healthmanagement/index.html">Health and Productivity Management</a></li>
														<li><a href="/english/sustainability/governance/index.html">Corporate Governance</a></li>
														<li><a href="/english/sustainability/evaluation/index.html">External Evaluations</a></li>
														<li><a href="/english/sustainability/activity/index.html">Activity Reports</a></li>
														<li><a href="/english/sustainability/data/index.html">Data</a></li>
														<li><a href="/english/sustainability/transparency/index.html">Chugai's Transparency Guidelines</a></li>
							
						</ul>
										</li>
					
				</ul>
			</nav>
		</div>
	</div>
	

	

	<footer id="footer">
		<div class="footerBottom">
			<div class="innerLarge">
				<div id="sns">
					<dl>
						<dt>Official Account</dt>
						<dd>
							<ul>
								<li><a href="https://twitter.com/chugai_cc" target="_blank"><img src="/common/images/footer-twitter-icon.png" alt="Twitter (Open in a new window)"></a></li>
								<li><a href="https://www.youtube.com/chugaijp" target="_blank"><img src="/common/images/footer-youtube-icon.png" alt="Youtube (Open in a new window)"></a></li>
								<li><a href="https://note.chugai-pharm.co.jp/" target="_blank" class="externalLink"><img src="/common/images/footer-note-icon.png" alt="note (CHUGAI DIGITAL) (Open in a new window)"></a></li>
							</ul>
						</dd>
					</dl>
				</div>
				<div class="annotation">
					<p>Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."</p>
				</div>
				<nav id="fsNavi">
					<ul>
						<li><a href="/english/rule/WebsiteUse/index.html">Terms and Conditions of Website Use</a></li>
						<li><a href="/english/rule/Privacy/index.html">Handling of Personal Information</a></li>
						<li><a href="/english/rule/sns/index.html">Social Media Policy</a></li>
						<li><a href="/english/rule/browser/index.html">Recommended Environment</a></li>
						<li><a href="/english/rule/accessibility/index.html">Web Accessibility</a></li>
					</ul>
				</nav>
			</div>
		</div>
		<p id="copyright">Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.</p>
	</footer>
	<div id="pagetop" style="bottom: -100px;"><a href="#"><img src="/common/images/pagetop.png" alt="Back to top"></a></div>
	<script src="//c.marsflag.com/mf/mfx/1.0/js/mfx-sbox.js" charset="UTF-8"></script> 
	
	<script type="text/javascript">
		!function(){
		  var G = GALFSRAM = window.GALFSRAM || {}
		  G.mfx = G.mfx || {}
		  G.mfx.router_mode = 'history'
		}();
	</script>

<script src="//c.marsflag.com/mf/mfx/1.0/js/mfx-serp.js" charset="UTF-8"></script>
<script src="/common/js/pushy.min.js"></script>
<script type="text/javascript" id="">(function(d,a){window.UserHeatTag=a;window[a]=window[a]||function(){(window[a].q=window[a].q||[]).push(arguments)};window[a].l=1*new Date;var b=document.createElement("script"),c=document.getElementsByTagName("script")[0];b.async=1;b.src=d;c.parentNode.insertBefore(b,c)})("//uh.nakanohito.jp/uhj2/uh.js","_uhtracker");_uhtracker({id:"uhkOzZl0YK"});</script>


<div id="outLink" class="lightBoxNone">
<div id="outLinkMessage">
<h3>You are now moving to an external website.</h3>
<p class="btnLink iconTab txtCenter"><a href="#" target="_blank" class="exceptionLink"><span>Access the link</span></a></p>
</div>
</div>

<script>
if (!window.GALFSRAM2) {
  window.GALFSRAM2 = {
    baseHref: '//c.marsflag.com/mf/gui/',
    hashParams: {cid: 'mf'}
  }
}
</script>
<script src="//c.marsflag.com/mf/gui/gui.js" charset="UTF-8"></script>


</body></html>